SIO will present three plenary sessions to complement keynotes for the 2015 International Conference November 14-16, in Boston, Massachusetts.
SIO is accepting workshop submissions for the 12th International Conference, which will be held Click here for the guidelines and form for submission. Workshop proposals must be authored by at least two organizers from two different institutions. Notifications concerning the proposal review will be sent in late May. Announcement of the call for abstract submissions will be made soon in Boston, Massachusetts. The submission deadline for the proposals is Eastern Time. .
On February 3, 2015, New York State Attorney General Eric Schneiderman released results of DNA testing of herbal supplements at major local retail chains. See the AG’s announcement.
Over half of Americans consume over 85,000 different supplements, including botanicals, spending $32 billion annually. Attorney General Schneiderman drew inspiration from a 2013 study performed at the University of Guelph in Canada, wherein a third of supplements tested with DNA barcoding did not find traces of the botanical being sold, only fillers. The Attorney General tested store brand bottles of St. John’s Wort, ginseng, Ginkgo biloba, valerian, garlic, and saw palmetto at major local chains: Wal-Mart, GNC, Target, and Walgreen Co. Testing of samples using DNA barcoding alone were performed by James Schulte II of Clarkson University in Potsdam, New York. Results indicated that only 21% of the store brand supplements contained DNA fragments of the botanical product sold. Additionally, DNA evidence of rice, beans, wheat, and some unidentified contaminants were found. In response to these findings, Mr. Schneiderman noted that these products should be removed from the stores immediately, with the burden of proof on the industry to demonstrate that botanical products can be validated for authenticity and safety.
The February 19, 2015 issue of Nature Reviews Cancer has published the Society for Integrative Oncology's (SIO) response to the perspectives on oncology authored by David Gorski, MD, "Integrative Oncology: Really the Best of Both Worlds?" which appeared in the September 18, 2014 issue. The SIO response, Integrative Oncology – Strong Science Is Needed for Better Patient Care1, was led by Immediate Past President Heather Greenlee, ND, PhD, and co-authored by President Suzanna Zick, ND, MPH, and Past Presidents David Rosenthal, MD, Lorenzo Cohen, PhD, Barrie Cassileth, PhD and Debu Tripathy, MD.
Three keynote speakers have been named for SIO's 12th International Conference to be held November 14-16 in Boston, Massachusetts. We are incredibly honored to have such diverse and distinguished presenters that touch on topics from neuroimaging to spirituality.
The Society for Integrative Oncology announced new officers and elected four new board members to serve three-year terms at its 2014 annual business meeting on October 28.
Mark your calendar: SIO’s 12th International Conference will be held November 15-16, 2015, with a theme of “Integrative Innovation” preceded by a first-ever Joint Conference on November 14 presented by SIO, the Society for Acupuncture Research, and Fascia Research Society. All in Boston, Massachusetts. Watch for updates!
Suzanna Zick, ND, MPH from University of Michigan Health System, has become President of SIO, effective at the Society’s International Conference on October 28, 2014. She served as President-Elect for the past year.
Dr. Zick received her degree as a Naturopathic Physician from the National College of Naturopathic Medicine in Portland, Oregon, and her Masters of Public Health in Epidemiology from the University of Michigan in Ann Arbor. Currently, Dr. Zick is a Research Associate Professor in Family Medicine and a Research Associate Professor of Environmental Health Sciences in the School of Public Health at the University of Michigan.
Shruti Jolly, MD, a board-certified radiation oncologist practicing at the University of Michigan and Ann Arbor VA hospitals, has joined the SIO Board of Trustees. Bringing a background in clinical work and research, Dr. Jolly sees “the addition of integrative therapies as crucial in the care of all patients, especially those with cancer who are suffering from their disease and its psychosocial burden.” For Dr. Jolly, “Incorporating these therapies as part of routine cancer care has become both a personal and professional goal.”
Jun Mao, MD, MSCE, Associate Professor, Department of Family Medicine and Community Health, University of Pennsylvania School of Medicine, was been elected President-Elect of the Society for Integrative Oncology (SIO) at the Society's International Conference on October 28, 2014.